Drug Profile
GSK 2838232
Alternative Names: GSK2838232Latest Information Update: 28 Jul 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Antivirals
- Mechanism of Action HIV replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported HIV infections
Most Recent Events
- 12 Feb 2022 Pharmacodynamics data from a preclinical studies in HIV infections treatment presented at the 29th Conference on Retroviruses and Opportunistic Infections (CROI-2022)
- 27 Sep 2021 No development reported - Phase-II for HIV infections treatment (Monotherapy, Treatment-naive) in Canada, USA (PO)
- 28 Apr 2019 No recent reports of development identified for phase-I development in HIV-infections(In volunteers) in USA (PO, Tablet)